- Home
- IMNN vs TENX Comparison
IMNN vs TENX Comparison
Compare IMNN & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNN
- TENX
- Stock Information
- Founded
- IMNN 1982
- TENX 1967
- Country
- IMNN United States
- TENX United States
- Employees
- IMNN N/A
- TENX N/A
- Industry
- IMNN Biotechnology: Pharmaceutical Preparations
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- IMNN Health Care
- TENX Health Care
- Exchange
- IMNN Nasdaq
- TENX Nasdaq
- Market Cap
- IMNN 12.2M
- TENX 19.5M
- IPO Year
- IMNN 1985
- TENX N/A
- Fundamental
- Price
- IMNN $0.83
- TENX $5.61
- Analyst Decision
- IMNN Strong Buy
- TENX Strong Buy
- Analyst Count
- IMNN 2
- TENX 4
- Target Price
- IMNN $20.50
- TENX $20.67
- AVG Volume (30 Days)
- IMNN 395.1K
- TENX 67.9K
- Earning Date
- IMNN 11-07-2024
- TENX 11-13-2024
- Dividend Yield
- IMNN N/A
- TENX N/A
- EPS Growth
- IMNN N/A
- TENX N/A
- EPS
- IMNN N/A
- TENX N/A
- Revenue
- IMNN N/A
- TENX N/A
- Revenue This Year
- IMNN N/A
- TENX N/A
- Revenue Next Year
- IMNN N/A
- TENX N/A
- P/E Ratio
- IMNN N/A
- TENX N/A
- Revenue Growth
- IMNN N/A
- TENX N/A
- 52 Week Low
- IMNN $0.48
- TENX $2.77
- 52 Week High
- IMNN $3.65
- TENX $27.36
- Technical
- Relative Strength Index (RSI)
- IMNN 47.27
- TENX 54.30
- Support Level
- IMNN $0.80
- TENX $5.70
- Resistance Level
- IMNN $0.88
- TENX $6.01
- Average True Range (ATR)
- IMNN 0.05
- TENX 0.47
- MACD
- IMNN 0.00
- TENX -0.08
- Stochastic Oscillator
- IMNN 25.00
- TENX 12.15
About IMNN Imunon Inc.
Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.